TCL Archive FDA Advisors Discuses Establishment of Standards for Showing Equivalence December 17, 1999
TCL Archive Phase III Trebananib Trial Fails OS Endpoint In Recurrent Platinum-Resistant Ovarian Cancer November 28, 2014
TCL Archive NCI Bypass Budget Justifies An Extra $900 Million In FY1992; Cancer costs Estimate At $80B A Year January 11, 1991
TCL Archive Investigators Unlocking Drug Resistance Secrets, NCI Study, Bristol-Myers Meeting Reports Show November 28, 1986
